Cabaletta Bio (NASDAQ:CABA) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Posted by Brian Himes on Nov 7th, 2026

Cabaletta Bio (NASDAQ:CABA – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04, FiscalAI reports.

Cabaletta Bio Price Performance

Shares of NASDAQ CABA traded up $0.02 during midday trading on Friday, hitting $1.30. The company’s stock had a trading volume of 2,997,885 shares, compared to its average volume of 4,904,986. The business’s fifty day simple moving average is $2.12 and its two-hundred day simple moving average is $2.82. Cabaletta Bio has a 1 year low of $1.18 and a 1 year high of $4.23. The firm has a market capitalization of $220.40 million, a price-to-earnings ratio of -0.92 and a beta of 3.56.

Analyst Upgrades and Downgrades

CABA has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Cabaletta Bio in a research report on Tuesday, September 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Thursday, October 15th. Wall Street Zen upgraded Cabaletta Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday. TD Cowen raised Cabaletta Bio to a “strong-buy” rating in a research note on Monday, August 24th. Finally, William Blair raised Cabaletta Bio to a “strong-buy” rating in a research note on Wednesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cabaletta Bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.60.

Read Our Latest Stock Analysis on CABA

About Cabaletta Bio

(Get Free Report)

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.